BIOMAT Database Logo BIOMAT Database Logo

Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. 1994

M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Department of Nuclear Medicine, St. Vincent's Hospital, Dublin, Ireland.

BACKGROUND Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. Previously, uPA was shown to be an independent prognostic marker in breast cancer. The aim of this study were to evaluate uPA as a prognostic marker in different subgroups of patients with breast cancer. METHODS Urokinase plasminogen activator was assayed by enzyme-linked immunosorbent assay in detergent extracts of human breast tumors. RESULTS Using both disease free interval (DFI) and overall survival (OS) as end points, uPA was an indicator of prognosis in the following groups of patients: those with positive axillary nodes, those who were estrogen receptor (ER)-positive, women younger than 50 years of age, and women older than 50 years of age. For patients with negative axillary lymph nodes, uPA was a significant prognostic marker using DFI as an end point and was almost statistically significant (P = 0.055) using OS as end point. In patients who were ER-negative, uPA levels showed no significant relationship with patient outcome. CONCLUSIONS Urokinase plasminogen activator is a significant prognostic marker in most of the major subgroups of patients with breast cancer and may be a marker for patients with negative axillary lymph nodes.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014568 Urokinase-Type Plasminogen Activator A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES. Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator

Related Publications

M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
June 1998, Clinical chemistry,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
June 1999, Journal of surgical oncology,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
May 1995, International journal of cancer,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
January 1998, Breast cancer research and treatment,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
November 1992, Cancer research,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
March 2011, Journal of internal medicine,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
March 1998, British journal of cancer,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.
January 2014, OncoTargets and therapy,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker in COVID-19 patients: a systematic review.
January 2024, European review for medical and pharmacological sciences,
M J Duffy, and D Reilly, and E McDermott, and N O'Higgins, and J J Fennelly, and P A Andreasen
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
October 1995, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!